Beta-2 microglobulin in patients on peritoneal dialysis and hemodialysis

A. Scalamogna, E. Imbasciati, A. De Vecchi, C. Castelnovo, B. Pagliari, V. De Cristofaro, C. Ponticelli

Research output: Contribution to journalArticlepeer-review


Serum β2 microglobulin (β2μ) levels were determined in 62 patients on chronic dialysis, divided according to the type of dialysis - cuprophane hemodialysis, chronic ambulatory peritoneal dialysis (CAPD), or CAPD started after 76 ± 47 months on cuprophane hemodialysis - and to residual urine output greater than 400 mL/day or less than 10 mL/day. In addition, for patients on CAPD, peritoneal excretion, peritoneal clearance, and urinary excretion of the protein were determined. In anuric patients serum β2μ levels were significantly higher in HD than in CAPD. In patients with residual urine output, serum concentrations of the microprotein were similar in HD and in CAPD. Significant differences were observed in β2μ serum levels and peritoneal clearances in patients switched to CAPD from hemodialysis as compared to those starting with CAPD. Peritoneal clearances of the microprotein was slightly and non-significantly greater in patients with urine output than in anuric patients.

Original languageEnglish
Pages (from-to)37-40
Number of pages4
JournalPeritoneal Dialysis International
Issue number1
Publication statusPublished - 1989

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'Beta-2 microglobulin in patients on peritoneal dialysis and hemodialysis'. Together they form a unique fingerprint.

Cite this